Quick Answer
Spyre Therapeutics, Inc. reported R&D Expense of $58.58 million for fiscal year 2022.
Spyre Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2022 | $58.58M | +2.6% |
| 2021 | $57.07M | -4.3% |
| 2020 | $59.64M | -7.7% |
| 2019 | $64.60M | +75.9% |
| 2018 | $36.72M | +60.9% |
| 2017 | $22.82M | +25.8% |
| 2016 | $18.14M | +58.4% |
| 2015 | $11.45M | +67.7% |
| 2014 | $6.83M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $13.78M | -18.9% | +15.0% |
| September 30, 2022 | $11.98M | -19.4% | -22.1% |
| June 30, 2022 | $15.37M | +13.2% | -9.5% |
| March 31, 2022 | $16.98M | +43.2% | +14.3% |
| September 30, 2021 | $14.85M | +19.3% | +9.4% |
| June 30, 2021 | $13.58M | -19.5% | +14.5% |
| March 31, 2021 | $11.86M | -18.6% | -4.8% |
| September 30, 2020 | $12.45M | -30.2% | -26.2% |
- Spyre Therapeutics, Inc. showed an increase of +2.6% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2022 period, Spyre Therapeutics, Inc.’s r&d expense has grown by 757.7% (from $6.83 million to $58.58 million).
- The most recent figure is from Spyre Therapeutics, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 2, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: